Semaglutide in the Treatment of Diabesity Individuals

Authors

Keywords:

obesity, mellitus diabetes, diabesity, semaglutide, glucagon-like peptide type 1 analog.

Abstract

Introduction: Semaglutide is a drug that contributes to the release of insulin from the pancreas and suppresses appetite, which makes it an important candidate for treating diabesity.

Objective: To describe the role of semaglutide in the treatment of diabesity individuals.

Methods: The necessary information to write this article was obtained in the 2022 two-month period January-February. The keywords used were obesity; Mellitus diabetes; diabesity; semaglutide; type 1 glucagon-like peptide analogue. The search engines corresponding to the Google Scholar, PubMed and SciElO databases were used. Different review, research and web pages were evaluated, which in general were published no more than 10 years ago, in Spanish, Portuguese or English and which dealt with the subject of study by title. Articles that did not address the relationship between diabetes and obesity, as well as treatment with glucagon-like peptide 1 analogues, were excluded. This allowed the consultation of 84 articles, 59 of them were referenced.

Conclusions: The use of semaglutide, as a complement to a diet and physical activity appropriate to the needs of patients with diabesity, brought about several effects that favor better evolution of this health problem, by optimizing glycemic control, contributing to the loss of weight and the improvement of certain comorbidities, including cardiovascular health.

 

 

Downloads

Download data is not yet available.

Author Biography

Jose Hernandez Rodriguez, Instituto de Endocrinolgia

Especialista de 1er y 2do grado en Endocrinologia

Profesor Auxiliar

Investigador Agregado

Published

2023-03-30

How to Cite

1.
Hernandez Rodriguez J. Semaglutide in the Treatment of Diabesity Individuals. Rev Cubana Med [Internet]. 2023 Mar. 30 [cited 2025 Mar. 14];62(1). Available from: https://revmedicina.sld.cu/index.php/med/article/view/2946